Bankruptcy auction2025-05-19confirmed
Regeneron Pharmaceuticals × 23andMe
Following its bankruptcy filing in March 2025, direct-to-consumer DNA testing company 23andMe sold its most valuable asset, its massive database of genetic information. [1, 6] Drug developer Regeneron Pharmaceuticals acquired the data bank for $256 million in a sale monitored by a court-appointed privacy ombudsman. [1]
Price paid
$256M
asset price, paid once
Losing bid
—
Per unit
17.0667
$ / customers
The asset
The company's data bank, including the genetic data and DNA samples from its approximately 15 million customers.
- 15M customers
The record
- Seller status
- Chapter 11
- Sector
- Genetic testing
- Modalities
- genomic_data
- Jurisdiction
- US
- Personal data
- The buyer pledged to comply with the seller's privacy policy, which allows customers to request data deletion. A court-appointed privacy ombudsman was assigned to monitor the sale process to ensure compliance. [1]
What it means if you hold data
This bankruptcy sale set a significant precedent for the treatment of large, sensitive, consumer-derived genetic datasets in insolvency proceedings. The price of approximately $17 per genome and the appointment of a privacy ombudsman are key benchmarks for future data asset sales. [1, 2]